Welcome to our dedicated page for 4D Molecular Therapeutics SEC filings (Ticker: FDMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
4D Molecular Therapeutics filings document financial results, clinical-development disclosures and governance matters for a Nasdaq-listed biotechnology issuer. Form 8-K reports furnish quarterly and annual results and include pipeline updates for 4D-150, the 4FRONT program in wet AMD, and related PRISM and SPECTRA studies in retinal disease.
The company’s proxy materials cover director elections, auditor ratification and executive-compensation votes. Other filings disclose officer appointments and compensatory arrangements, equity awards, registered common stock, and capital-structure actions involving exchanges of common stock for pre-funded warrants with exercise limitations and beneficial-ownership blockers.
Form 4 filed for 4D Molecular Therapeutics, Inc. (FDMT) reports a routine stock-option grant to director John F. Milligan on 06/17/2025. The award covers 33,750 options to purchase common shares at an exercise price of $4.15. The options were automatically granted under the company’s non-employee director compensation program.
Vesting is structured as follows:
- One-third (11,250 options) vests on 06/17/2026
- Remaining options vest in equal monthly installments until fully vested on 06/17/2028
- All options accelerate to full vesting upon a qualifying Change in Control
Following the grant, Milligan beneficially owns 33,750 derivative securities. No open-market purchases or sales of common stock were reported, and there is no cash outlay for the director at grant date. Investors should view this filing as standard governance practice rather than a signal of immediate financial impact.
On June 17, 2025, 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) held its 2025 virtual Annual Meeting of Stockholders. Of the 46.3 million outstanding shares, 38.5 million (≈83%) were represented in person or by proxy.
- Director elections (Proposal 1): All three Class II nominees were re-elected to serve until the 2028 AGM. Support ranged from 84.5% (Dr. Charles P. Theuer) to 98.9% (Susannah Gray).
- Auditor ratification (Proposal 2): Shareholders overwhelmingly confirmed PricewaterhouseCoopers LLP for FY 2025 (≈99.8% in favor).
- Say-on-pay (Proposal 3): 98.7% of votes cast approved FY 2024 executive compensation on an advisory basis.
- Say-on-pay frequency (Proposal 4): A majority (≈99%) selected one-year intervals for future advisory votes; the board will follow this cadence.
No other business or material transactions were reported. The results signal continued shareholder endorsement of the company’s leadership, compensation practices, and external auditor.